Loading...
•
Jun 30, 2023
Ultragenyx Q2 2023 Earnings Report
Ultragenyx reported Q2 2023 financial results with total revenue of $108.3 million, a 21% increase compared to Q2 2022.
Key Takeaways
Ultragenyx reported a total revenue of $108.3 million for the second quarter of 2023, representing a 21% increase compared to the second quarter of 2022. Crysvita revenue in North America grew by 19% to $61.3 million. The company reaffirmed its 2023 total revenue guidance between $425 million and $450 million.
Total revenue for Q2 2023 was $108.3 million, a 21% increase year-over-year.
Crysvita revenue for Q2 2023 was $83.0 million, a 20% increase year-over-year.
Dojolvi revenue for Q2 2023 was $16.5 million.
The company reaffirmed its 2023 revenue guidance for total revenue, Crysvita, and Dojolvi.
Revenue by Segment
Forward Guidance
The company expects total revenue to be in the range of $425 million to $450 million, Crysvita revenue in the range of $325 million to $340 million, and Dojolvi revenue in the range of $65 million to $75 million for the full year 2023. Net cash used in operations is expected to be around $400 million.
Positive Outlook
- Total revenue in the range of $425 million to $450 million
- Crysvita revenue in the range of $325 million to $340 million.
- Dojolvi revenue in the range of $65 million to $75 million
- Net Cash Used in Operations to be around $400 million
- Two Phase 3 studies enrolling, additional Phase 2 data expected in mid-October
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...